SequelSEC

HeartSciences Inc. HSCS

Finance Services · CIK 0001468492 · Fiscal year ends 0430 · Bank

Revenue
$4.52K
Fiscal year ended 2026-07-31
Net income
-$10.26M
Fiscal year ended 2026-07-31
Total assets
$3.74M
Fiscal year ended 2026-07-31

HeartSciences Inc. (HSCS) reported revenue of $4.52K and net income of -$10.26M for the fiscal year ended 2026-07-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from HeartSciences Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Finance Services.

Banks, brokers and insurers present a top line that is not comparable with an operating company’s revenue: it is reported net of interest expense, or as premiums earned, depending on the filer. The figures are the filer’s own and are traceable to the filing; the comparison across classes is what does not hold.

Income

HeartSciences Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-31
Revenue$4.52K
Cost of revenue$1.77K
Gross profit$2.75K
Operating income-$9.48M
Net income-$10.26M
Research & development$2.75M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$6.73M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

HeartSciences Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-31
Cash & equivalents$29.91K
Total assets$3.74M
Current assets$811.77K
Total liabilities$5.77M
Current liabilities$5.63M
Total equity incl. NCI-$2.03M
Temporary (mezzanine) equityUnavailable
Inventory$402.99K
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.02M

Cash flow

HeartSciences Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-31
Operating cash flow-$6.79M
Capital expendituresUnavailable
Investing cash flow-$323.74K
Financing cash flow$4.35M
Net change in cash-$2.76M
Stock-based compensation$1.88M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

HeartSciences Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-31
Free cash flowUnavailable
Gross margin60.9%
Operating margin-209733.1%
FCF marginUnavailable
SBC / revenue41529.4%
Current ratio0.14x
Revenue YoY growthUnavailable
Net margin-227024.2%
R&D / revenue60819.5%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HSCS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-09-14View SEC filing
10-K · Filed 2026-07-23View SEC filing
10-Q · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-12-15View SEC filing
10-Q · Filed 2025-09-11View SEC filing
10-K · Filed 2025-07-24View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.